Clinical Trials Directory

Trials / Completed

CompletedNCT00421044

A Study of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function

An Open-label, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Patupilone in Patients With Advanced Solid Tumors and Varying Degrees of Hepatic Function

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
14 (actual)
Sponsor
Novartis Pharmaceuticals · Industry
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Patients who participated in the core EPO2121 study and did not clinically progress may participate in this extension protocol to further evaluate the safety, tolerability, and efficacy of patupilone.

Conditions

Interventions

TypeNameDescription
DRUGPatupilone/EPO906

Timeline

Start date
2006-05-01
Primary completion
2008-02-01
First posted
2007-01-11
Last updated
2012-01-11

Locations

3 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT00421044. Inclusion in this directory is not an endorsement.